STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript

STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript

Seeking Alpha • May 28, 2026

STAAR Surgical Announces Participation in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas.

Business Wire • May 21, 2026

STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround

STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.

Seeking Alpha • May 16, 2026

Why It's Time To Take Profits In This Top-Rated Medical Stock

Staar Surgical shares catapulted Thursday after the eye surgery outlet obliterated first-quarter profit expectations.

Investors Business Daily • May 14, 2026

STAAR Surgical Q1 Earnings Call Highlights

STAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following a difficult 2025.

MarketBeat • May 14, 2026

STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript

STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 14, 2026

Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates

Staar Surgical (STAA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago.

Zacks Investment Research • May 13, 2026

Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 13, 2026

STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and bus.

Business Wire • May 4, 2026

Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 29, 2026